close

Agreements

1 204 205 206 207 208 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2013-01-14 OcellO (The Netherlands) Merus (The Netherlands) screening services to profile bispecific antibodies

collaboration
services

Cancer - Oncology Services contract
2013-01-14 AstraZeneca (UK) Vanderbilt University (USA) candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia R&D
licensing
CNS diseases - Neurodegenerative diseases - Mental diseases - Psychiatric diseases
2013-01-14 Boehringer Ingelheim (Germany) Horizon Discovery (UK) Discovery Toolbox including isogenic models and phenotypic assays and genome editing technologies

undisclosed cancers

R&D
services
Cancer - Oncology
2013-01-09 Evotec (Germany) Yale University (USA) novel exploratory drug targets and compounds metabolic diseases, CNS diseases, immunological diseases, cancer, glioblastoma

R&D

Metabolic diseases - CNS diseases - Immunological diseases - Cancer - Oncology R&D agreement
2013-01-08 Priaxon (Germany) GSK (UK) small molecule modulators of protein-protein-interactions undisclosed

R&D

undisclosed R&D agreement
2013-01-08 to-BBB (The Netherlands) ALS Therapy Development Institute (USA) CNS-targeted liposomal drug delivery system (G-Technology) amyotrophic lateral sclerosis

R&D

Neurodegenerative diseases - Neuromuscular diseases R&D agreement
2013-01-08 Santaris Pharma (Denmark) miRagen Therapeutics (USA) microRNA therapeutics (LNA drugs against up to six additional microRNA targets) cardiovascular diseases

licensing

Cardiovascular diseases Licensing agreement
2013-01-08 Octoplus (The Netherlands) Sanofi (France)

services

Services contract
2013-01-08 LFB, Laboratoire français du fractionnement des biotechnologies (France) Shin Poong (South Korea) biotech medicinal products including ATryn® and FVIIa

joint-venture
production
manufacturing

Hemtological diseases - Rare diseases Joint-venture agreement
2013-01-08 Hoopika Biotech (Austria)

nomination

Cancer - Oncology - Infectious diseases Nomination
2013-01-08 Hoopika Biotech (Austria)

nomination

Cancer - Oncology - Infectious diseases Nomination
2013-01-07 Evotec (Germany) MedImmune (USA - global biologics arm of AstraZeneca (UK) beta cell regeneration assets and capabilities including EVT770 diabetes

licensing
collaboration

Metabolic diseases Licensing agreement
2013-01-07 Ethris (Germany) Shire (UK) RNA-based therapeutics monogenic genetic diseases

R&D

Genetic diseases - Rare diseases R&D agreement
2013-01-07 Qiagen (The Netherlands) Drug Response Dx (Germany) companion diagnostic rheumatoid arthritis

equity investment
licensing option

Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Licensing agreement
2013-01-07 Qiagen (The Netherlands) Insight Genetics (USA) RET, ROS1 and DEPDC1 biomarkers non-small cell lung cancer (NSCLC)

licensing

Cancer - Oncology Licensing agreement
2013-01-07 Qiagen (The Netherlands) Inserm Transfert (France) biomarker for mutations of the HSP110 gene colorectal cancer

licensing

Cancer - Oncology Licensing agreement
2013-01-07 Adaptimmune (UK) Life Technologies (USA) intellectual property portfolio for methods of expanding and activating T cells transduced with engineered T cell receptors (TCR)

licensing

Licensing agreement
2013-01-07 DebioPharm (Switzerland) Chugai (Japan) FF284 (Debio 1347) and its companion diagnostic

development
licensing
commercialisation

Cancer - Oncology Development agreement
2013-01-07 Ariad Pharmaceuticals (USA - MA) Newcastle University (UK) ponatinib (Iclusig®) chronic myeloid leukemia

clinical research

Cancer - Oncology Clinical research agreement
2013-01-07 Dako (Denmark) Eli Lilly (USA) companion diagnostic tests for an investigational oncology medicine undisclosed cancer

development

Cancer - Oncology Development agreement